Company Overview
Pliant Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company dedicated to the discovery and development of integrin-based therapeutics designed for the treatment of solid tumors. The firm functions within the Healthcare sector, specifically the Biotechnology industry, a classification that signifies its engagement in high-risk, high-reward research and development phases rather than established commercial product sales. The company's current market capitalization stands at $72.44M, while its reported annual revenue and earnings growth figures are listed as N/A in available data, and the organization employs 49 individuals. These valuation and scale metrics indicate that Pliant Therapeutics is a small-cap entity with a limited workforce, operating primarily on the front end of its product lifecycle where lead candidates like PLN-101095 are under investigation rather than generating substantial commercial cash flow.
Financial Health
The financial statements for the trailing twelve months show revenue as N/A, a net income of $-149,344,000, and an EBITDA of $-148,376,992. The significant gap between the reported revenue (N/A) and the substantial net loss reveals a cost structure dominated by research and development expenses and operational overhead typical of a clinical-stage biotech firm with no significant commercial revenue stream to offset costs. Free cash flow for the period was $-84,559,000, which indicates that the company is consuming cash to fund its operations and development programs rather than generating liquidity from business activities. This negative cash flow position necessitates careful capital management, as the firm relies on existing reserves or external financing to sustain its scientific pipeline. Analysis of the three primary margins shows a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%, figures that collectively indicate the company is not yet profitable and that revenue, if any, is entirely consumed by operating expenses. The balance sheet holds $190.94M in cash against $29.11M in debt, resulting in a debt-to-equity ratio of 16.06, which suggests a leveraged capital structure where debt obligations are present but manageable relative to equity, though the company remains cash-burn positive. The current ratio is reported at 12.00, a metric that indicates robust short-term liquidity as the company possesses twelve dollars of current assets for every single dollar of current liabilities. Return on Equity is -61.5% and Return on Assets is -30.2%, metrics that reveal management is currently destroying shareholder value through losses rather than generating returns, a common characteristic for biotech firms pre-revenue.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A, while the forward P/E is -0.96, a difference that implies the market expects earnings to remain negative or volatile in the near term as the company moves through clinical trials. The price-to-book ratio is 0.40, indicating that the stock is trading at a significant discount to its book value, which often reflects the market's skepticism regarding the realization of the company's intangible assets and future pipeline potential. Alternative valuation metrics include a price-to-sales ratio listed as N/A and an EV/EBITDA of 0.60, suggesting that investors are valuing the firm based on enterprise value relative to earnings before interest, taxes, depreciation, and amortization despite current losses. The 52-week high for the stock was $1.95 and the 52-week low was $1.09, placing the current trading environment within a specific historical range that reflects recent market sentiment. The beta value is 1.28, which means the stock exhibits higher price volatility relative to the broader market, moving more aggressively than the average stock in response to market-wide fluctuations.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, indicating that the company is in a stage where historical growth rates are not yet applicable or reported in standard comparative formats. Since earnings are currently negative at $-149,344,000, the concept of earnings growing faster than revenue is not applicable in the traditional sense, as the primary focus remains on achieving commercial milestones rather than expanding profit margins. Pliant Therapeutics does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which explains that the company reinvests all available resources and potential future earnings back into its research and development pipeline rather than distributing income to shareholders. The overall growth and income profile for Pliant Therapeutics is characterized by a lack of current commercial growth and income generation, with the financial structure entirely dependent on capitalizing the clinical-stage asset PLN-101095 to eventually transition into a revenue-generating entity.